Cargando…
Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691927/ https://www.ncbi.nlm.nih.gov/pubmed/37531287 http://dx.doi.org/10.1093/rheumatology/kead388 |
| _version_ | 1785152831733366784 |
|---|---|
| author | Hazlewood, Glen S |
| author_facet | Hazlewood, Glen S |
| author_sort | Hazlewood, Glen S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10691927 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106919272023-12-02 Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors Hazlewood, Glen S Rheumatology (Oxford) Editorial Oxford University Press 2023-08-02 /pmc/articles/PMC10691927/ /pubmed/37531287 http://dx.doi.org/10.1093/rheumatology/kead388 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Editorial Hazlewood, Glen S Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title | Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title_full | Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title_fullStr | Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title_full_unstemmed | Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title_short | Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors |
| title_sort | risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of jak inhibitors |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691927/ https://www.ncbi.nlm.nih.gov/pubmed/37531287 http://dx.doi.org/10.1093/rheumatology/kead388 |
| work_keys_str_mv | AT hazlewoodglens riskbenefittradeoffsinrheumatologyrofecoxibrevisitedintheeraofjakinhibitors |